The current landscape of multiple myeloma treatment.
Cavo
Michele
M
Seràgnoli Institute of Hematology and Medical Oncology, Bologna University School of Medicine, Bologna, Italy.
Attal
Michel
M
Gertz
Morie A
MA
Giralt
Sergio
S
Ludwig
Heinz
H
Morgan
Gareth J
GJ
Anderson
Kenneth C
KC
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000639:trends; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D033581:Stem Cell Transplantation / Q000639:trends; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D014182:Transplantation, Autologous
D013792:Thalidomide; D000077269:Lenalidomide